Patient journey mapping

What?

A leading global biopharmaceutical research organisation were seeking support with the development of patient facing materials to explain important clinical study information to participants in a Phase 3 randomized, controlled study.

Why?

The clinical study involves self-administration of the study drug at the onset of suspected disease symptoms. For this reason, patients in the study would require additional resources to support them in recognising those symptoms and knowing how to self-administer the study drug. They would also need to be kept engaged over the course of the 2.5-years that they may be enrolled in the study.

How?

In order to determine the required patient materials for each stage of the patients’ journey through the study, a strategic analysis of each stage was required. The patient journey was mapped and analysed in a series workshops with key study stakeholders. The workshop process facilitated agreement and common understanding of the patient journey and informational needs.

Results?

With the development of the patient journey map, stakeholders gained a deeper appreciation for where information gaps were likely to arise and identified the need for a set of core patient-facing materials in support of the study.